ClinicalTrials.gg
CompletedNCT03916081Updated Feb 13, 2023Results posted

Safety and Efficacy of ARQ-151 Cream in Adolescents and Adults With Atopic Dermatitis

A Phase 2 interventional study of Roflumilast Cream 0.05% and Roflumilast Cream 0.15% in Atopic Dermatitis, sponsored by Arcutis Biotherapeutics, Inc.. Completed at 20 sites in 2 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2023-02-13.

Sponsored by Arcutis Biotherapeutics, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
136
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing roflumilast in Dermatitis, Atopic — 4 open to participants now, 4 under way, 1 of them phase 3. Roflumilast · Dermatitis, Atopic.

Enrollment
7th of 13
136 · median 136
Started
2019
with 1 other
Phase 2
4 of 13
1 open now
Registered
2nd of 13
by date
Lead sponsor
8 of 13
Arcutis Biotherapeutics, Inc.

Among the 13 studies testing roflumilast in Dermatitis, Atopic, this one is the 7th largest by enrollment, is one of 2 that started in 2019, is one of 4 in phase 2, and was the 2nd registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

4 of the 13 studies testing roflumilast in Dermatitis, Atopic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About roflumilast

Roflumilast: first FDA approval 2011 (DALIRESP), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing roflumilast in Dermatitis, Atopic, or all of them as a file.
02

Study summary

The study will assess the safety, pharmacokinetics (PK), and efficacy of different doses of roflumilast (ARQ-151) cream (0.05% and 0.15%) vs placebo applied once daily (QD) for 28 days by adolescents and adults with atopic dermatitis.

Read the detailed description

This is a parallel group, double blind, vehicle-controlled study in which roflumilast cream 0.05% or 0.15% or vehicle is applied QD x 28 days to adolescent and adult subjects with atopic dermatitis. A subset of subjects will have serial PK testing, which will include the first few adolescents and adults enrolled in the study.

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants legally competent to sign and give or, in the case of adolescents, assent with consent of a parent(s) or legal guardian, as required by local laws.
  2. Males and females ages 12 years and older (inclusive) at the time of consent.
  3. Clinical diagnosis of active atopic dermatitis for at least 6 months.
  4. BSA (Body Surface Area) involvement of at least 2% but no more than 25% at Baseline.
  5. vIGA-AD (validated Investigator Global Assessment-Atopic Dermatitis) score of 'mild' ('2') or 'moderate ('3') at Baseline.
  6. EASI (Eczema Area and Severity Index) score of ≥ 5 at Baseline.
  7. Females of must have a negative serum pregnancy test at Screening and, if sexually active, agree to use throughout the trial.
  8. In good health as judged by the Investigator, based on medical history, physical examination, and clinical tests.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with any serious medical condition or physical examination or test abnormality that would prevent study participation or place the subject at significant risk.
  2. Evidence of skin conditions other than AD (atopic dermatitis) that would interfere with evaluation of the effect of the study medication.
  3. Pregnant or lactating women or women planning to become pregnant during the study.
  4. Known allergies to in ARQ-151 cream.
  5. Subjects who cannot discontinue the use of strong P-450 cytochrome inducers or inhibitors .
  6. Subjects who are unwilling to refrain from using a tanning bed as well as outdoor tanning or excessive sun exposure.
  7. Subjects with unstable AD or who cannot discontinue systemic and/or topical therapies for the treatment of AD.
  8. Known or suspected:

    • severe renal insufficiency or moderate to severe hepatic disorders ( B or C)
    • history of chronic infectious disease (e.g., , , or (HIV))
    • within last 5 years, a history of severe depression, suicidal ideation
  9. Previous treatment with ARQ-151.
  10. Subjects with a history of chronic alcohol or drug abuse in past 6 months.
  11. Current or a history of cancer within 5 years with the exception of fully excised skin basal cell carcinoma, cutaneous squamous cell carcinoma or carcinoma in situ of the cervix.
  12. Subjects with active infection that requires oral or intravenous administration of antibiotics, antifungal or antiviral agents.
  13. Subjects with a history of a major surgery within 8 weeks prior to Baseline or has a major surgery planned during the study.
  14. Subjects with any condition which makes them unsuitable for clinical study participation or are family members of the clinical study site, clinical study staff, sponsor, or family members of enrolled subjects.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
136 participants (actual)

Study arms

  • Active comparator
    Roflumilast Cream 0.05%

    Participants apply roflumilast cream 0.05% QD for 28 days.

    Drug: Roflumilast Cream 0.05%

  • Active comparator
    Roflumilast Cream 0.15%

    Participants apply roflumilast cream 0.15% QD for 28 days.

    Drug: Roflumilast Cream 0.15%

  • Placebo comparator
    Vehicle Cream

    Participants apply vehicle cream QD for 28 days.

    Drug: Vehicle Cream

Interventions

  • Roflumilast 0.05% cream for topical application

    Also known as: ARQ-151

  • Roflumilast 0.15% cream for topical application

    Also known as: ARQ-151

  • DrugVehicle Cream

    Inactive vehicle cream matched to roflumilast cream for topical application.

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in Eczema Area and Severity Index (EASI) Total Score at Week 4

    The least squares (LS) mean (SD) change from baseline in EASI Total Score at Week 4 is reported. The EASI is an instrument to measure the severity and extent of AD. The body is first divided into 4 areas: head (10% of skin), arms (20%), trunk (30%), and legs (40%). Then, the area affected is scored from 0 (0% involvement) to 6 (90-100% involvement), and severity is scored from 0 ('none') to 3 ('severe'). The EASI combines the area affected and severity ratings to get a final composite score ranging from 0 (no disease) to 72 (maximal disease). Note that palms and soles were treated as appropriate but were not counted towards any measurements of EASI.

    Time frame: Baseline and Week 4

Secondary outcomes

  1. Percentage Change From Baseline in EASI Total Score

    The LS mean (SD) percentage change from baseline in EASI Total Score at Weeks 1, 2, and 4 is reported. The EASI is an instrument to measure the severity and extent of AD. The body is first divided into 4 areas: head (10% of skin), arms (20%), trunk (30%), and legs (40%). Then, the area affected is scored from 0 (0% involvement) to 6 (90-100% involvement), and severity is scored from 0 ('none') to 3 ('severe'). The EASI combines the area affected and severity ratings to get a final composite score ranging from 0 (no disease) to 72 (maximal disease). Note that palms and soles were treated as appropriate but were not counted towards any measurements of EASI.

    Time frame: Baseline and Weeks 1, 2, and 4

  2. Mean Change From Baseline in EASI Total Score at Weeks 1 and 2

    The LS mean (SD) change from baseline in EASI Total Score at Weeks 1 and 2 is reported. The EASI is an instrument to measure the severity and extent of AD. The body is first divided into 4 areas: head (10% of skin), arms (20%), trunk (30%), and legs (40%). Then, the area affected is scored from 0 (0% involvement) to 6 (90-100% involvement), and severity is scored from 0 ('none') to 3 ('severe'). The EASI combines the area affected and severity ratings to get a final composite score ranging from 0 (no disease) to 72 (maximal disease). Note that palms and soles were treated as appropriate but were not counted towards any measurements of EASI.

    Time frame: Baseline and Weeks 1 and 2

  3. Number of Participants Achieving a 50% Decrease From Baseline in EASI Score (EASI-50)

    The number of participants with a decrease of at least 50% from the baseline EASI total score is presented. The EASI is an instrument to measure the severity and extent of AD. The body is first divided into 4 areas: head (10% of skin), arms (20%), trunk (30%), and legs (40%). Then, the area affected is scored from 0 (0% involvement) to 6 (90-100% involvement), and severity is scored from 0 ('none') to 3 ('severe'). The EASI combines the area affected and severity ratings to get a final composite score ranging from 0 (no disease) to 72 (maximal disease), with positive results indicating an increase from baseline in EASI total score (i.e., increased symptoms) and negative results indicating a decrease from baseline score (i.e., decreased symptoms). Note that palms and soles were treated as appropriate but were not counted towards any measurements of EASI.

    Time frame: Baseline and Weeks 1, 2, and 4

  4. Number of Participants Achieving a 75% Decrease From Baseline in EASI Score (EASI-75)

    The number of participants with a decrease of at least 75% from the baseline EASI total score is presented. The EASI is an instrument to measure the severity and extent of AD. The body is first divided into 4 areas: head (10% of skin), arms (20%), trunk (30%), and legs (40%). Then, the area affected is scored from 0 (0% involvement) to 6 (90-100% involvement), and severity is scored from 0 ('none') to 3 ('severe'). The EASI combines the area affected and severity ratings to get a final composite score ranging from 0 (no disease) to 72 (maximal disease), with positive results indicating an increase from baseline in EASI total score (i.e., increased symptoms) and negative results indicating a decrease from baseline score (i.e., decreased symptoms). Note that palms and soles were treated as appropriate but were not counted towards any measurements of EASI.

    Time frame: Baseline and Weeks 1, 2, and 4

  5. Number of Participants Achieving a 90% Decrease From Baseline in EASI Score (EASI-90)

    The number of participants with a decrease of at least 90% from the baseline EASI total score is presented. The EASI is an instrument to measure the severity and extent of AD. The body is first divided into 4 areas: head (10% of skin), arms (20%), trunk (30%), and legs (40%). Then, the area affected is scored from 0 (0% involvement) to 6 (90-100% involvement), and severity is scored from 0 ('none') to 3 ('severe'). The EASI combines the area affected and severity ratings to get a final composite score ranging from 0 (no disease) to 72 (maximal disease), with positive results indicating an increase from baseline in EASI total score (i.e., increased symptoms) and negative results indicating a decrease from baseline score (i.e., decreased symptoms). Note that palms and soles were treated as appropriate but were not counted towards any measurements of EASI. In some instances, it was not possible to compare roflumilast to vehicle due to low number of cases.

    Time frame: Baseline and Weeks 1, 2, and 4

  6. Number of Participants Achieving a 100% Decrease From Baseline in EASI Score (EASI-100)

    The number of participants with a decrease of 100% from the baseline EASI total score is presented. The EASI is an instrument to measure the severity and extent of AD. The body is first divided into 4 areas: head (10% of skin), arms (20%), trunk (30%), and legs (40%). Then, the area affected is scored from 0 (0% involvement) to 6 (90-100% involvement), and severity is scored from 0 ('none') to 3 ('severe'). The EASI combines the area affected and severity ratings to get a final composite score ranging from 0 (no disease) to 72 (maximal disease), with positive results indicating an increase from baseline in EASI total score (i.e., increased symptoms) and negative results indicating a decrease from baseline score (i.e., decreased symptoms). Note that palms and soles were treated as appropriate but were not counted towards any measurements of EASI. In some instances, it was not possible to compare roflumilast to vehicle due to low number of cases.

    Time frame: Baseline and Weeks 1, 2, and 4

  7. Mean Change From Baseline in Body Surface Area (BSA) Involvement

    The LS mean (SE) change from baseline in BSA involvement at Weeks 1, 2, and 4 is presented. The BSA affected by AD was determined by the subject's hand method, where the subject's hand (including fingers) surface area was assumed to equal 1% of BSA. Negative scores indicate improvement of symptoms, whereas positive scores indicate worsening.

    Time frame: Baseline and Weeks 1, 2, and 4

  8. Worse Itch Numerical Rating Score (WI-NRS) Score Change

    The LS mean (SE) change from baseline in WI-NRS score is presented. The WI-NRS is a simple, single item scale to assess the subject-reported severity of this symptom, on a scale ranging from 0 ("no itch") to 10 ("worst imaginable itch") the subject experienced in the previous 24 hours. Higher scores indicate greater symptom severity.

    Time frame: Baseline and Weeks 1, 2, and 4

  9. Number of Participants Achieving ≥4-Point Improvement in WI-NRS Pruritus Score

    The number of participants achieving a ≥4-point improvement from Baseline in WI-NRS score is presented. The WI-NRS is a simple, single item scale to assess the subject-reported severity of this symptom, on a scale ranging from 0 ("no itch") to 10 ("worst imaginable itch") the subject experienced in the previous 24 hours. Higher scores indicate greater symptom severity.

    Time frame: Baseline and Weeks 1, 2, and 4

07

Results

Posted Feb 13, 2023

Participant flow

Adolescent (12 to 17 years of age) and adult (≥18 years of age) male and female participants with mild to moderate atopic dermatitis (AD) were enrolled at 3 study sites in Canada and 19 sites in the US.

Participant flow — Overall Study
MilestoneRoflumilast Cream 0.05%Roflumilast Cream 0.15%Vehicle Cream
Started464545
Completed424442
Not completed413
Withdrew: Adverse event100
Withdrew: Physician decision001
Withdrew: Lost to follow-up010
Withdrew: Withdrawal by subject301
Withdrew: Worsening of ad001

Outcome measures

PrimaryMean Change From Baseline in Eczema Area and Severity Index (EASI) Total Score at Week 4

The least squares (LS) mean (SD) change from baseline in EASI Total Score at Week 4 is reported. The EASI is an instrument to measure the severity and extent of AD. The body is first divided into 4 areas: head (10% of skin), arms (20%), trunk (30%), and legs (40%). Then, the area affected is scored from 0 (0% involvement) to 6 (90-100% involvement), and severity is scored from 0 ('none') to 3 ('severe'). The EASI combines the area affected and severity ratings to get a final composite score ranging from 0 (no disease) to 72 (maximal disease). Note that palms and soles were treated as appropriate but were not counted towards any measurements of EASI.

Time frame:
Baseline and Week 4
Reported as:
Least squares mean · score on a scale
Mean Change From Baseline in Eczema Area and Severity Index (EASI) Total Score at Week 4
score on a scaleRoflumilast Cream 0.05%Roflumilast Cream 0.15%Vehicle Cream
Mean Change From Baseline in Eczema Area and Severity Index (EASI) Total Score at Week 4-6.03 ± 0.503-6.44 ± 0.492-4.84 ± 0.492
Statistical analysis
  • Roflumilast Cream 0.05% vs Vehicle Cream · MMRM · p = 0.356 (MMRM = mixed effects model for repeated measures vIGA-AD = validated Investigator Global Assessment scale for Atopic Dermatitis) · Ls mean difference vs vehicle: -1.18 · 95% CI -2.983 to 0.619Change from BL MMRM model includes treatment, visit, vIGA-AD strata, treatment-by-visit interaction as fixed effects and baseline EASI as a covariate.
  • Roflumilast Cream 0.15% vs Vehicle Cream · MMRM · p = 0.097 · Ls mean difference vs vehicle: -1.60 · 95% CI -3.382 to 0.178Change from BL MMRM model includes treatment, visit, vIGA-AD strata, treatment-by-visit interaction as fixed effects and baseline EASI as a covariate.
SecondaryPercentage Change From Baseline in EASI Total Score

The LS mean (SD) percentage change from baseline in EASI Total Score at Weeks 1, 2, and 4 is reported. The EASI is an instrument to measure the severity and extent of AD. The body is first divided into 4 areas: head (10% of skin), arms (20%), trunk (30%), and legs (40%). Then, the area affected is scored from 0 (0% involvement) to 6 (90-100% involvement), and severity is scored from 0 ('none') to 3 ('severe'). The EASI combines the area affected and severity ratings to get a final composite score ranging from 0 (no disease) to 72 (maximal disease). Note that palms and soles were treated as appropriate but were not counted towards any measurements of EASI.

Time frame:
Baseline and Weeks 1, 2, and 4
Reported as:
Least squares mean · percent change
Percentage Change From Baseline in EASI Total Score
percent changeRoflumilast Cream 0.05%Roflumilast Cream 0.15%Vehicle Cream
Week 1-35.77 ± 4.297-34.67 ± 4.273-24.39 ± 4.279
Week 2-54.30 ± 4.663-57.65 ± 4.567-48.48 ± 4.571
Week 4-69.37 ± 4.643-72.32 ± 4.546-55.84 ± 4.551
Statistical analysis
  • Roflumilast Cream 0.05% vs Vehicle Cream · MMRM · p = 0.248 · Ls mean difference: -11.37 · 95% CI -26.789 to 4.044Change from BL MMRM model includes treatment, visit, vIGA-AD strata, treatment-by-visit interaction as fixed effects and baseline EASI as a covariate.
  • Roflumilast Cream 0.15% vs Vehicle Cream · MMRM · p = 0.349 · Ls mean difference: -10.28 · 95% CI -25.666 to 5.114Change from BL MMRM model includes treatment, visit, vIGA-AD strata, treatment-by-visit interaction as fixed effects and baseline EASI as a covariate.
  • Roflumilast Cream 0.05% vs Vehicle Cream · MMRM · p = 0.912 · Ls mean difference: -5.82 · -22.520% CI -22.520 to 10.880Change from BL MMRM model includes treatment, visit, vIGA-AD strata, treatment-by-visit interaction as fixed effects and baseline EASI as a covariate.
  • Roflumilast Cream 0.15% vs Vehicle Cream · MMRM · p = 0.548 · Ls mean difference: -9.17 · 95% CI -25.686 to 7.341Change from BL MMRM model includes treatment, visit, vIGA-AD strata, treatment-by-visit interaction as fixed effects and baseline EASI as a covariate.
  • Roflumilast Cream 0.05% vs Vehicle Cream · MMRM · p = 0.164 · Ls mean difference: -13.53 · 95% CI -30.157 to 3.097Change from BL MMRM model includes treatment, visit, vIGA-AD strata, treatment-by-visit interaction as fixed effects and baseline EASI as a covariate.
  • Roflumilast Cream 0.15% vs Vehicle Cream · MMRM · p = 0.049 · Ls mean difference: -16.48 · 95% CI -32.921 to -0.048Change from BL MMRM model includes treatment, visit, vIGA-AD strata, treatment-by-visit interaction as fixed effects and baseline EASI as a covariate.
SecondaryMean Change From Baseline in EASI Total Score at Weeks 1 and 2

The LS mean (SD) change from baseline in EASI Total Score at Weeks 1 and 2 is reported. The EASI is an instrument to measure the severity and extent of AD. The body is first divided into 4 areas: head (10% of skin), arms (20%), trunk (30%), and legs (40%). Then, the area affected is scored from 0 (0% involvement) to 6 (90-100% involvement), and severity is scored from 0 ('none') to 3 ('severe'). The EASI combines the area affected and severity ratings to get a final composite score ranging from 0 (no disease) to 72 (maximal disease). Note that palms and soles were treated as appropriate but were not counted towards any measurements of EASI.

Time frame:
Baseline and Weeks 1 and 2
Reported as:
Least squares mean · score on a scale
Mean Change From Baseline in EASI Total Score at Weeks 1 and 2
score on a scaleRoflumilast Cream 0.05%Roflumilast Cream 0.15%Vehicle Cream
Week 1-3.11 ± 0.416-2.77 ± 0.57-2.19 ± 0.414
Week 2-4.80 ± 0.479-5.02 ± 0.469-4.31 ± 0.470
Statistical analysis
  • Roflumilast Cream 0.05% vs Vehicle Cream · MMRM · p = 0.440 · Ls mean difference: -0.92 · 95% CI -2.412 to 0.568Change from BL MMRM model includes treatment, visit, vIGA-AD strata, treatment-by-visit interaction as fixed effects and baseline EASI as a covariate.
  • Roflumilast Cream 0.15% vs Vehicle Cream · MMRM · p = 0.875 · Ls mean difference: -0.57 · 95% CI -2.061 to 0.914Change from BL MMRM model includes treatment, visit, vIGA-AD strata, treatment-by-visit interaction as fixed effects and baseline EASI as a covariate.
SecondaryNumber of Participants Achieving a 50% Decrease From Baseline in EASI Score (EASI-50)

The number of participants with a decrease of at least 50% from the baseline EASI total score is presented. The EASI is an instrument to measure the severity and extent of AD. The body is first divided into 4 areas: head (10% of skin), arms (20%), trunk (30%), and legs (40%). Then, the area affected is scored from 0 (0% involvement) to 6 (90-100% involvement), and severity is scored from 0 ('none') to 3 ('severe'). The EASI combines the area affected and severity ratings to get a final composite score ranging from 0 (no disease) to 72 (maximal disease), with positive results indicating an increase from baseline in EASI total score (i.e., increased symptoms) and negative results indicating a decrease from baseline score (i.e., decreased symptoms). Note that palms and soles were treated as appropriate but were not counted towards any measurements of EASI.

Time frame:
Baseline and Weeks 1, 2, and 4
Reported as:
Count of participants · Participants
Number of Participants Achieving a 50% Decrease From Baseline in EASI Score (EASI-50)
ParticipantsRoflumilast Cream 0.05%Roflumilast Cream 0.15%Vehicle Cream
Week 1141110
Week 2272322
Week 4323325
Statistical analysis
  • Roflumilast Cream 0.05% vs Vehicle Cream · Cochran-Mantel-Haenszel · p = 0.352Baseline vIGA-AD was included as stratification factor.
  • Roflumilast Cream 0.15% vs Vehicle Cream · Cochran-Mantel-Haenszel · p = 0.803Baseline vIGA-AD was included as stratification factor.
  • Roflumilast Cream 0.05% vs Vehicle Cream · Cochran-Mantel-Haenszel · p = 0.250Baseline vIGA-AD was included as stratification factor.
  • Roflumilast Cream 0.15% vs Vehicle Cream · Cochran-Mantel-Haenszel · p = 0.756Baseline vIGA-AD was included as stratification factor.
  • Roflumilast Cream 0.05% vs Vehicle Cream · Cochran-Mantel-Haenszel · p = 0.097Baseline vIGA-AD was included as stratification factor.
  • Roflumilast Cream 0.15% vs Vehicle Cream · Cochran-Mantel-Haenszel · p = 0.054Baseline vIGA-AD was included as stratification factor.
SecondaryNumber of Participants Achieving a 75% Decrease From Baseline in EASI Score (EASI-75)

The number of participants with a decrease of at least 75% from the baseline EASI total score is presented. The EASI is an instrument to measure the severity and extent of AD. The body is first divided into 4 areas: head (10% of skin), arms (20%), trunk (30%), and legs (40%). Then, the area affected is scored from 0 (0% involvement) to 6 (90-100% involvement), and severity is scored from 0 ('none') to 3 ('severe'). The EASI combines the area affected and severity ratings to get a final composite score ranging from 0 (no disease) to 72 (maximal disease), with positive results indicating an increase from baseline in EASI total score (i.e., increased symptoms) and negative results indicating a decrease from baseline score (i.e., decreased symptoms). Note that palms and soles were treated as appropriate but were not counted towards any measurements of EASI.

Time frame:
Baseline and Weeks 1, 2, and 4
Reported as:
Count of participants · Participants
Number of Participants Achieving a 75% Decrease From Baseline in EASI Score (EASI-75)
ParticipantsRoflumilast Cream 0.05%Roflumilast Cream 0.15%Vehicle Cream
Week 1461
Week 281411
Week 4262314
Statistical analysis
  • Roflumilast Cream 0.05% vs Vehicle Cream · Cochran-Mantel-Haenszel · p = 0.178Baseline vIGA-AD was included as stratification factor.
  • Roflumilast Cream 0.15% vs Vehicle Cream · Cochran-Mantel-Haenszel · p = 0.046Baseline vIGA-AD was included as stratification factor.
  • Roflumilast Cream 0.05% vs Vehicle Cream · Cochran-Mantel-Haenszel · p = 0.469Baseline vIGA-AD was included as stratification factor.
  • Roflumilast Cream 0.15% vs Vehicle Cream · Cochran-Mantel-Haenszel · p = 0.446Baseline vIGA-AD was included as stratification factor.
  • Roflumilast Cream 0.05% vs Vehicle Cream · Cochran-Mantel-Haenszel · p = 0.009Baseline vIGA-AD was included as stratification factor.
  • Roflumilast Cream 0.15% vs Vehicle Cream · Cochran-Mantel-Haenszel · p = 0.045Baseline vIGA-AD was included as stratification factor.
SecondaryNumber of Participants Achieving a 90% Decrease From Baseline in EASI Score (EASI-90)

The number of participants with a decrease of at least 90% from the baseline EASI total score is presented. The EASI is an instrument to measure the severity and extent of AD. The body is first divided into 4 areas: head (10% of skin), arms (20%), trunk (30%), and legs (40%). Then, the area affected is scored from 0 (0% involvement) to 6 (90-100% involvement), and severity is scored from 0 ('none') to 3 ('severe'). The EASI combines the area affected and severity ratings to get a final composite score ranging from 0 (no disease) to 72 (maximal disease), with positive results indicating an increase from baseline in EASI total score (i.e., increased symptoms) and negative results indicating a decrease from baseline score (i.e., decreased symptoms). Note that palms and soles were treated as appropriate but were not counted towards any measurements of EASI. In some instances, it was not possible to compare roflumilast to vehicle due to low number of cases.

Time frame:
Baseline and Weeks 1, 2, and 4
Reported as:
Count of participants · Participants
Number of Participants Achieving a 90% Decrease From Baseline in EASI Score (EASI-90)
ParticipantsRoflumilast Cream 0.05%Roflumilast Cream 0.15%Vehicle Cream
Week 1010
Week 2164
Week 48128
Statistical analysis
  • Roflumilast Cream 0.15% vs Vehicle Cream · Cochran-Mantel-Haenszel · p = 0.317Baseline vIGA-AD was included as stratification factor.
  • Roflumilast Cream 0.05% vs Vehicle Cream · Cochran-Mantel-Haenszel · p = 0.182Baseline vIGA-AD was included as stratification factor.
  • Roflumilast Cream 0.15% vs Vehicle Cream · Cochran-Mantel-Haenszel · p = 0.485Baseline vIGA-AD was included as stratification factor.
  • Roflumilast Cream 0.05% vs Vehicle Cream · Cochran-Mantel-Haenszel · p = 0.913Baseline vIGA-AD was included as stratification factor.
  • Roflumilast Cream 0.05% vs Vehicle Cream · Cochran-Mantel-Haenszel · p = 0.288Baseline vIGA-AD was included as stratification factor.
SecondaryNumber of Participants Achieving a 100% Decrease From Baseline in EASI Score (EASI-100)

The number of participants with a decrease of 100% from the baseline EASI total score is presented. The EASI is an instrument to measure the severity and extent of AD. The body is first divided into 4 areas: head (10% of skin), arms (20%), trunk (30%), and legs (40%). Then, the area affected is scored from 0 (0% involvement) to 6 (90-100% involvement), and severity is scored from 0 ('none') to 3 ('severe'). The EASI combines the area affected and severity ratings to get a final composite score ranging from 0 (no disease) to 72 (maximal disease), with positive results indicating an increase from baseline in EASI total score (i.e., increased symptoms) and negative results indicating a decrease from baseline score (i.e., decreased symptoms). Note that palms and soles were treated as appropriate but were not counted towards any measurements of EASI. In some instances, it was not possible to compare roflumilast to vehicle due to low number of cases.

Time frame:
Baseline and Weeks 1, 2, and 4
Reported as:
Count of participants · Participants
Number of Participants Achieving a 100% Decrease From Baseline in EASI Score (EASI-100)
ParticipantsRoflumilast Cream 0.05%Roflumilast Cream 0.15%Vehicle Cream
Week 1000
Week 2120
Week 4151
Statistical analysis
  • Roflumilast Cream 0.05% vs Vehicle Cream · Cochran-Mantel-Haenszel · p = 0.340Baseline vIGA-AD was included as stratification factor.
  • Roflumilast Cream 0.15% vs Vehicle Cream · Cochran-Mantel-Haenszel · p = 0.146Baseline vIGA-AD was included as stratification factor.
  • Roflumilast Cream 0.05% vs Vehicle Cream · Cochran-Mantel-Haenszel · p = 0.967Baseline vIGA-AD was included as stratification factor.
  • Roflumilast Cream 0.15% vs Vehicle Cream · Cochran-Mantel-Haenszel · p = 0.088Baseline vIGA-AD was included as stratification factor.
SecondaryMean Change From Baseline in Body Surface Area (BSA) Involvement

The LS mean (SE) change from baseline in BSA involvement at Weeks 1, 2, and 4 is presented. The BSA affected by AD was determined by the subject's hand method, where the subject's hand (including fingers) surface area was assumed to equal 1% of BSA. Negative scores indicate improvement of symptoms, whereas positive scores indicate worsening.

Time frame:
Baseline and Weeks 1, 2, and 4
Reported as:
Least squares mean · percentage of BSA affected
Mean Change From Baseline in Body Surface Area (BSA) Involvement
percentage of BSA affectedRoflumilast Cream 0.05%Roflumilast Cream 0.15%Vehicle Cream
Week 1-1.19 ± 0.407-1.67 ± 0.407-1.57 ± 0.405
Week 2-2.69 ± 0.580-3.63 ± 0.570-3.29 ± 0.568
Week 4-4.41 ± 0.658-5.10 ± 0.645-4.16 ± 0.644
Statistical analysis
  • Roflumilast Cream 0.05% vs Vehicle Cream · MMRM · p = 0.989 · Ls mean difference: 0.38 · 95% CI -1.098 to 1.852Change from BL MMRM model includes treatment, visit, vIGA-AD strata, treatment-by-visit interaction as fixed effects and baseline BSA as a covariate.
  • Roflumilast Cream 0.15% vs Vehicle Cream · MMRM · p = >0.999 · Ls mean difference: -0.10 · 95% CI -1.566 to 1.367Change from BL MMRM model includes treatment, visit, vIGA-AD strata, treatment-by-visit interaction as fixed effects and baseline BSA as a covariate.
  • Roflumilast Cream 0.05% vs Vehicle Cream · MMRM · p = 0.966 · Ls mean difference: 0.60 · 95% CI -1.510 to 2.702Change from BL MMRM model includes treatment, visit, vIGA-AD strata, treatment-by-visit interaction as fixed effects and baseline BSA as a covariate.
  • Roflumilast Cream 0.15% vs Vehicle Cream · MMRM · p = 0.999 · Ls mean difference: -0.34 · 95% CI -2.415 to 1.744Change from BL MMRM model includes treatment, visit, vIGA-AD strata, treatment-by-visit interaction as fixed effects and baseline BSA as a covariate.
  • Roflumilast Cream 0.05% vs Vehicle Cream · MMRM · p = >0.999 · Ls mean difference: -0.25 · 95% CI -2.624 to 2.119Change from BL MMRM model includes treatment, visit, vIGA-AD strata, treatment-by-visit interaction as fixed effects and baseline BSA as a covariate.
  • Roflumilast Cream 0.15% vs Vehicle Cream · MMRM · p = 0.798 · Ls mean difference: -0.94 · 95% CI -3.285 to 1.398Change from BL MMRM model includes treatment, visit, vIGA-AD strata, treatment-by-visit interaction as fixed effects and baseline BSA as a covariate.
SecondaryWorse Itch Numerical Rating Score (WI-NRS) Score Change

The LS mean (SE) change from baseline in WI-NRS score is presented. The WI-NRS is a simple, single item scale to assess the subject-reported severity of this symptom, on a scale ranging from 0 ("no itch") to 10 ("worst imaginable itch") the subject experienced in the previous 24 hours. Higher scores indicate greater symptom severity.

Time frame:
Baseline and Weeks 1, 2, and 4
Reported as:
Least squares mean · score on a scale
Worse Itch Numerical Rating Score (WI-NRS) Score Change
score on a scaleRoflumilast Cream 0.05%Roflumilast Cream 0.15%Vehicle Cream
Week 1-2.21 ± 2.13-2.46 ± 0.361-1.7 ± 2.52
Week 2-2.46 ± 0.415-2.76 ± 0.413-2.04 ± 0.408
Week 4-3.34 ± 0.449-3.23 ± 0.444-2.73 ± 0.440
Statistical analysis
  • Roflumilast Cream 0.05% vs Vehicle Cream · MMRM · p = 0.466 · Ls mean difference: -0.78 · 95% CI -2.075 to 0.506Change from BL MMRM model includes treatment, visit, vIGA-AD strata, treatment-by-visit interaction as fixed effects and baseline WI-NRS as a covariate.
  • Roflumilast Cream 0.15% vs Vehicle Cream · MMRM · p = 0.180 · Ls mean difference: -1.03 · 95% CI -2.322 to 0.255Change from BL MMRM model includes treatment, visit, vIGA-AD strata, treatment-by-visit interaction as fixed effects and baseline WI-NRS as a covariate.
  • Roflumilast Cream 0.05% vs Vehicle Cream · MMRM · p = 0.967 · Ls mean difference: -0.43 · 95% CI -1.921 to 1.069Change from BL MMRM model includes treatment, visit, vIGA-AD strata, treatment-by-visit interaction as fixed effects and baseline WI-NRS as a covariate.
  • Roflumilast Cream 0.15% vs Vehicle Cream · MMRM · p = 0.684 · Ls mean difference: -0.72 · 95% CI -2.205 to 0.762Change from BL MMRM model includes treatment, visit, vIGA-AD strata, treatment-by-visit interaction as fixed effects and baseline WI-NRS as a covariate.
  • Roflumilast Cream 0.05% vs Vehicle Cream · MMRM · p = 0.856 · Ls mean difference: -0.61 · 95% CI -2.221 to 1.003Change from BL MMRM model includes treatment, visit, vIGA-AD strata, treatment-by-visit interaction as fixed effects and baseline WI-NRS as a covariate.
  • Roflumilast Cream 0.15% vs Vehicle Cream · MMRM · p = 0.932 · Ls mean difference: -0.51 · 95% CI -2.105 to 1.089Change from BL MMRM model includes treatment, visit, vIGA-AD strata, treatment-by-visit interaction as fixed effects and baseline WI-NRS as a covariate.
SecondaryNumber of Participants Achieving ≥4-Point Improvement in WI-NRS Pruritus Score

The number of participants achieving a ≥4-point improvement from Baseline in WI-NRS score is presented. The WI-NRS is a simple, single item scale to assess the subject-reported severity of this symptom, on a scale ranging from 0 ("no itch") to 10 ("worst imaginable itch") the subject experienced in the previous 24 hours. Higher scores indicate greater symptom severity.

Time frame:
Baseline and Weeks 1, 2, and 4
Reported as:
Count of participants · Participants
Number of Participants Achieving ≥4-Point Improvement in WI-NRS Pruritus Score
ParticipantsRoflumilast Cream 0.05%Roflumilast Cream 0.15%Vehicle Cream
Week 111159
Week 2101516
Week 4211718
Statistical analysis
  • Roflumilast Cream 0.05% vs Vehicle Cream · Cochran-Mantel-Haenszel · p = 0.637v-IGA-AD included as a stratification factor.
  • Roflumilast Cream 0.15% vs Vehicle Cream · Cochran-Mantel-Haenszel · p = 0.124v-IGA-AD included as a stratification factor.
  • Roflumilast Cream 0.05% vs Vehicle Cream · Cochran-Mantel-Haenszel · p = 0.196v-IGA-AD included as a stratification factor.
  • Roflumilast Cream 0.15% vs Vehicle Cream · Cochran-Mantel-Haenszel · p = 0.985v-IGA-AD included as a stratification factor.
  • Roflumilast Cream 0.05% vs Vehicle Cream · Cochran-Mantel-Haenszel · p = 0.401v-IGA-AD included as a stratification factor.
  • Roflumilast Cream 0.15% vs Vehicle Cream · Cochran-Mantel-Haenszel · p = 0.996v-IGA-AD included as a stratification factor.

Adverse events

Collected over Up to 32 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Roflumilast Cream 0.05%0/46 (0%)1/46 (2.2%)0/46 (0%)
Roflumilast Cream 0.15%0/45 (0%)0/45 (0%)0/45 (0%)
Vehicle Cream0/45 (0%)0/45 (0%)0/45 (0%)
Most frequent serious events
Most frequent serious events
EventRoflumilast Cream 0.05%Roflumilast Cream 0.15%Vehicle Cream
Traumatic spinal cord compressionInjury, poisoning and procedural complications1/460/450/45

Baseline characteristics

Age, Continuous
Age, Continuous(years)Roflumilast Cream 0.05%Roflumilast Cream 0.15%Vehicle CreamTotal
Mean44.3 ± 16.9838.0 ± 16.4642.4 ± 17.6441.6 ± 17.11
Sex: Female, Male
Sex: Female, Male(Participants)Roflumilast Cream 0.05%Roflumilast Cream 0.15%Vehicle CreamTotal
Female31332993
Male15121643
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Roflumilast Cream 0.05%Roflumilast Cream 0.15%Vehicle CreamTotal
Hispanic or Latino9101332
Not Hispanic or Latino363532103
Unknown or Not Reported1001
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Roflumilast Cream 0.05%Roflumilast Cream 0.15%Vehicle CreamTotal
American Indian or Alaska Native2002
Asian1528
Native Hawaiian or Other Pacific Islander0000
Black or African American11141136
White32243288
More than one race0202
Unknown or Not Reported0000
Baseline Eczema Area and Severity Index (EASI) Score
Baseline Eczema Area and Severity Index (EASI) Score(score on a scale)Roflumilast Cream 0.05%Roflumilast Cream 0.15%Vehicle CreamTotal
Mean8.44 ± 4.1499.50 ± 4.0979.20 ± 3.8779.04 ± 4.039
Baseline Body Surface Area (BSA) Score
Baseline Body Surface Area (BSA) Score(percentage of body surface area)Roflumilast Cream 0.05%Roflumilast Cream 0.15%Vehicle CreamTotal
Mean8.4 ± 7.119.6 ± 5.9910.5 ± 6.629.5 ± 6.60
Baseline Worst Itch Numerical Rating Scale (WI-NRS) Score
Baseline Worst Itch Numerical Rating Scale (WI-NRS) Score(score on a scale)Roflumilast Cream 0.05%Roflumilast Cream 0.15%Vehicle CreamTotal
Mean6.48 ± 1.9866.60 ± 2.0497.20 ± 2.1066.76 ± 2.057
08

Study locations

20 sites
  • Arcutis Clinical Site 25
    Scottsdale, Arizona 85254, United States
  • Arcutis Clinical Site 01
    San Diego, California 92123, United States
  • Arcutis Clinical Site 19
    Hialeah, Florida 33016, United States
  • Arcutis Clinical Site 18
    Miami, Florida 33174, United States
  • Arcutis Clinical Site 17
    Sanford, Florida 32771, United States
  • Arcutis Clinical Site 16
    Boise, Idaho 83713, United States
  • Arcutis Clinical Site 12
    Indianapolis, Indiana 46250, United States
  • Arcutis Clinical Site 13
    Plainfield, Indiana 46168, United States
  • Arcutis Clinical Site 15
    Metairie, Louisiana 70006, United States
  • Arcutis Clinical Site 03
    Fridley, Minnesota 55432, United States
  • Arcutis Clinical Site 02
    High Point, North Carolina 27262, United States
  • Arcutis Clinical Site 08
    Bexley, Ohio 43209, United States
  • Arcutis Clinical Site 23
    Pittsburgh, Pennsylvania 15213, United States
  • Arcutis Clinical Site 20
    Murfreesboro, Tennessee 37130, United States
  • Arcutis Clinical Site 09
    College Station, Texas 77845, United States
  • Arcutis Clinical Site 04
    San Antonio, Texas 78213, United States
  • Arcutis Clinical Site 21
    Richmond, Virginia 23224, United States
  • Arcutis Clinical Site 14
    Cobourg, Ontario K9A 4J9, Canada
  • Arcutis Clinical Site 10
    Richmond Hill, Ontario L4B 1A5, Canada
  • Arcutis Clinical Site 06
    Montréal, Quebec H2K 4L5, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2019 to primary completion in Nov 2019, 5 months.

Results were first posted in Feb 2023, 3 years 3 months after primary completion. A results delay was requested in Oct 2020.

Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's 5 months is below that.

Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 10, 2019
First posted
Apr 16, 2019
StartActual
May 31, 2019
Primary completionActual
Nov 4, 2019
CompletionActual
Nov 4, 2019
Results delay requested
Oct 19, 2020
Results first posted
Feb 13, 2023
Last update
Feb 13, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03916081
Responsible party
Sponsor
First posted
Apr 16, 2019
Start date
May 31, 2019
Primary completion
Nov 4, 2019
Completion
Nov 4, 2019
Results posted
Feb 13, 2023
Last update
Feb 13, 2023

Study contacts

David Berk, MD
study director · Arcutis Biotherapeutics, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Roflumilast

Start the discussion